Viracta Therapeutics Announces the Appointment of Flavia Borellini, Ph D , and Jane F Barlow, M D , MPH, MBA, to its Board of Directors
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Viracta Therapeutics Announces the Appointment of Flavia Borellini, Ph D , and Jane F Barlow, M D , MPH, MBA, to its Board of Directors
biospace.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospace.com Daily Mail and Mail on Sunday newspapers.
Viracta Therapeutics Strengthens Company Leadership with New Appointments to the Board of Directors and Management Team
Stephen Rubino, Ph.D., MBA and Barry J. Simon, M.D. appointed to the Board of Directors
Cheryl A. Madsen, RAC appointed as Senior Vice President, Regulatory Affairs
News provided by
Share this article
Share this article
SAN DIEGO, March 4, 2021 /PRNewswire/ Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that it has strengthened its leadership team with the appointments of Drs. Stephen Rubino and Barry J. Simon to the Board of Directors, the addition of Cheryl A. Madsen, RAC as Senior Vice President, Regulatory Affairs, and the promotion of several members of the management team.